EUCTR2006-002321-23-IT进行中（未招募）不适用
A Phase 2 Study of LY573636 Administered a san Intravenous Infusion on Day 1 of a 21-Day cycle as third-line Treatment in patients with unresectable, metastatic non-Small Cell lung cancer - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Have a histologic and/or cytologic diagnosis of metastatic NSCLC that is unresectable. Patients with unresectable, Stage IIIB disease are also eligible. 2 Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors RECIST . 3 Are at least 18 years of age. 4 Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group ECOG Scale 5 Have received two previous systemic treatment regimens for metastatic NSCLC, one of which must have been platinum-based. 6 Must have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, or other investigational therapy for at least 30 days 6 weeks for mitomycin-C or nitrosoureas before study enrollment and recovered from the acute effects of therapy except alopecia . 7 Have adequate organ function including Bone Marrow Reserve Absolute neutrophil count ANC 8805;1.5 x 109/L prior to treatment, platelets 8805;100 x 109/L, and hemoglobin 8805;8 g/dL transfusions are not allowed to reach 8 g/dL prior to enrollment . Hepatic Bilirubin 1.5 times the upper limit of normal ULN . Alkaline phosphatase and transaminases ALT and AST 5 times ULN Renal Serum creatinine at or below the ULN. No known active renal disease 8 Have a serum albumin level 8805; 30 g/L or 3.0 g/dL. 9 Males and females with reproductive potential should use medically approved contraceptive precautions during the trial and for 6 months following the last dose of study drug. 10 Exhibit patient compliance and geographic proximity that allow for adequate follow-up. 11 Have given written informed consent approved by Lilly and the ethical review board ERB governing the site.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •12 Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. 13 Have received 8805; 3 previous systemic treatment regimens for metastatic NSCLC. 14 Patients with documented central nervous system or leptomeningeal metastasis brain metastasis at the time of study entry. Patients with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before study entry to rule out occult brain metastasis. 15 Patients with serious concomitant disorders, including active bacterial, fungal, or viral infection, incompatible with the study at the discretion of the investigator . 16 Patients with a second primary malignancy that could affect compliance with the protocol or interpretation of the results. NOTE Patients with adequately treated carcinoma of the skin excluding melanoma and patients with a prior history of malignancy who have been disease-free for more than 2 years are eligible. 17 Patients with serious preexisting medical conditions at the investigator s discretion . 18 Patients actively receiving warfarin Coumadin therapy for treatment of venous thrombosis or other prothrombotic conditions. NOTE Patients receiving low dose 1 mg daily warfarin will be allowed in this study. For those patients, more frequent monitoring of PT INR /aPTT will be required. 19 Persons who have previously completed or withdrawn from this study or any other study investigating LY573636. 20 Women who are pregnant or lactating.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer - JZACEUCTR2006-002321-23-DEEli Lilly and Company Limited60
进行中（未招募）
1 期
Estudio fase II de LY573636 sódico administrado como tratamiento de segunda o tercera línea en pacientes con sarcoma de tejido blando irresecable o metastásicoA Phase 2 Study of LY573636-sodium Administered as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft Tissue Sarcoma - JZADSarcoma de tejido blando irresecable o metastasicoMedDRA version: 9.1Level: LLTClassification code 10042863Term: Synovial sarcomaMedDRA version: 9.1Level: LLTClassification code 10024189Term: LeiomyosarcomaMedDRA version: 9.1Level: LLTClassification code 10024633Term: Liposarcoma stage unspecifiedMedDRA version: 9.1Level: LLTClassification code 10025552Term: Malignant fibrous histiocytomaMedDRA version: 9.1Level: LLTClassification code 10045515Term: Undifferentiated sarcomaEUCTR2007-001402-24-ESilly S.A.50
进行中（未招募）
1 期
SB-061 for the Treatment of Symptomatic Osteoarthritis of the KneeOsteoarthritis of the KneeMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2019-004515-31-DKordic Bioscience Clinical Development A/S278
进行中（未招募）
不适用
A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG - NDpatients with epithelial ovarian cancer who have received no more than 2 prior systemic treatment regimens for platinum-resistant disease.MedDRA version: 6.1Level: PTClassification code 10061328EUCTR2006-005971-17-ITELI LILLY50
进行中（未招募）
1 期
A study in T-ALL/T-LBL PatientsT-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)EUCTR2014-005024-10-SEEli Lilly and Company36